ClinicalTrials.gg
RecruitingNCT07259005BHBEUpdated Dec 2, 2025

Breathe Hard to Breathe Easy: Online Breathwork-Assisted Therapy for Social Anxiety

An interventional study of Breathwork-Assisted Therapy 1 and Breathwork-Assisted Therapy 2 in Social Anxiety, sponsored by Maastricht University. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Maastricht University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to investigate the potential of supplementing psychotherapy with breathing techniques as a new online therapeutic approach to reduce social anxiety (SA). Clinically significant SA affects a substantial portion of the population (about 13%) and is associated with strong negative feelings of shame and anxiety in social settings. Such emotional distress leads to impairment in personal, relational, and professional functioning and may result in increasing degrees of social isolation.

In response to the demand for improved treatments for SA, this project aims to explore the efficacy of a novel treatment approach integrating online psychotherapy with online breathwork sessions designed to induce ASC.

We will recruit 96 individuals with SA, who will be randomly divided into two groups: one group will receive the new combined breathwork-assisted psychotherapy, and the other an active control intervention that does not induce ASC. Over the treatment duration, the effectiveness of these treatments will be closely monitored using established psychological scales and by observing patients in live interactions before and after therapy.

This project is expected to open the way to a more accessible and effective treatment option for a large group of people struggling with SA. More broadly, the findings will also contribute to our understanding of how ASC, induced through breathing techniques, can be used therapeutically. This could change the way a variety of mental health conditions (e.g., other anxiety-related conditions and depression) are treated, making a substantial impact on public health and the way mental health disorders are approached and managed.

Read the detailed description

Rationale: Clinically significant social anxiety affects a substantial portion of the population (about 13%) and is associated with strong negative feelings of shame, anxiety in social settings, and significant personal, relational and professional impairment. Importantly, recent estimates suggest that between half and one-third of these individuals do not respond to conventional therapies. Recent findings show better treatment outcomes for a variety of mental health conditions when psychological treatments are complemented by sessions during which participants experience altered states of consciousness. In response to the demand for improved treatments for social anxiety, this project aims to investigate the efficacy of a novel treatment approach integrating online therapy with online breathwork sessions designed to induce altered states of consciousness.

Objective: The aim is to test online-delivered breathwork-assisted therapy to reduce social anxiety.

Study design: The study will be conducted according to a randomized, experimental, between-groups design with two breathwork-assisted therapy interventions. The intervention will consist of a total of 6 sessions including two preparation sessions, two breathwork sessions, and two integration session.

Study population: 96 adult individuals with social anxiety (Liebowitz Social Anxiety Scale score > 49).

Intervention (if applicable): Breathwork-assisted therapy 1 or breathwork-assisted therapy 2.

Main study parameters/endpoints: Primary outcomes will be self-reported levels of social anxiety. Performance and physiological response in a social interaction task will be used as a secondary measure.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Participants will be invited to the lab twice for the administration of behavioral tasks and two more times to participate to the breathwork sessions. Each visit will last about 2 hours. The treatment will run online and includes activities for a total 6.5h. Finally, we estimate a cumulative 1 hour to fill in all questionnaires. The total maximum load per participant is therefore 11.5 hours. Breathwork can produce an increased state of physiological arousal accompanied by elevations in heart rate and blood pressure that are considered safe in appropriately screened individuals. It also produces altered states of consciousness that may, in some cases, be characterized by transient anxiety. Participants may also experience discomfort during the social interaction task. In case the treatment yields the expected results, a potential benefit may be the reduction of social anxiety.

02

Conditions studied

  • Social Anxiety

Keywords

  • social anxiety
  • breathwork
  • psychotherapy
  • breathwork-assisted psychotherapy
  • altered states of consciousness
03

In context

Lead sponsor

Maastricht University is the lead sponsor of 97 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fluent in the English or Dutch language
  • Aged between 18 and 65
  • LSAS score ≥50
  • Written

Exclusion criteria

Exclusion Criteria:

  • Hypotension (diastolic \< 60 mmHg; systolic > 90 mmHg) or hypertension (diastolic > 90 mmHg; systolic > 140 mmHg)
  • History or presence of psychotic or bipolar disorders or first-degree relatives suffering from this
  • History of respiratory or cardiovascular/heart problems or disease, cerebral aneurysm
  • History of fainting or syncope, epilepsy or seizures
  • History of panic disorder or panic attacks,
  • Having had adverse reactions with prior breathwork sessions (i.e., fainting),
  • Pregnancy, thinking one might be pregnant, trying to get pregnant, or breastfeeding
  • Any problems affecting the ability to pace breathing (i.e., active/chronic respiratory infection including blocked nose/cough/cold/fever, etc.), breathlessness, abnormally slow breathing (bradypnea), or abnormally fast breathing (tachypnoea), any other physical/mental health conditions or current life events impairing the ability to engage in activities involving breath control
  • Taking any regular medication other than the pill, including medications to reduce blood pressure (i.e., Ramipril or other ACE-inhibitors) and beta-blockers (i.e., Propranolol).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Breathwork-assisted Therapy 1

    The investigational treatment will include two preparation sessions, two breathwork sessions, and two integration sessions.

    Behavioral: Breathwork-Assisted Therapy 1

  • Active comparator
    Breathwork-Assisted Therapy 2

    The control treatment will include two preparation sessions, two breathwork sessions, and two integration sessions.

    Behavioral: Breathwork-Assisted Therapy 2

Interventions

  • BehavioralBreathwork-Assisted Therapy 1

    The investigational treatment will include two preparation sessions, two breathwork sessions, and two integration sessions.

  • BehavioralBreathwork-Assisted Therapy 2

    The comparator treatment will include two preparation sessions, two breathwork sessions, and two integration sessions.

06

What researchers measure

Primary outcomes

  1. Liebowitz Social Anxiety Scale

    The LSAS (25) is a widely recognized instrument designed to assess the severity of SA. The LSAS measures both the fear and avoidance associated with social and performance situations. It consists of 24 items, divided into two subscales: 13 items addressing social interaction situations and 11 items focusing on performance situations. Each item is rated on a Likert scale from 0 (none) to 3 (severe) for fear, and from 0 (never) to 3 (usually) for avoidance, yielding a total possible score range of 0 to 144. The scale's dual focus allows for a comprehensive assessment of SA, making it a valuable tool for both therapy settings and research. The LSAS has demonstrated strong psychometric properties, including high internal consistency and test-retest reliability (26). It is also sensitive to changes in symptomatology, which makes it useful for evaluating treatment outcomes (27). The scale's validity has been established through correlations with other

    Time frame: The LSAS will be administered at all study timepoints: baseline, after each treatment session, 1 week and 1 month after the end of treatment.

Secondary outcomes

  1. Getting Acquainted Task

    The GAT is an assessment tool used to evaluate SA by observing how an individual performs in a structured social interaction (29). The participant will be paired with a confederate and asked to engage in a conversation to get to know each other. This scenario is designed to elicit behaviors and responses indicative of SA, such as difficulty initiating conversation, discomfort, or avoidance behaviors. The task will involve different confederates at the two assessment timepoints to reduce habituation effects and will be video recorded and analyzed later for social performance assessment (29, 30). The assessment will be carried out by blinded raters on two dimensions: anxious appearance (fidgeting, blushing, laughing nervously and feelings of nervousness) and social behavior (making eye contact, completing of sentences, coherence, silences, listening, showing interest, responding) (29).

    Time frame: The GAT will be administered at baseline and 1 week after the last treatment session.

  2. Heart Rate Variability

    During the GAT heart-rate variability (HRV) will be assessed through the use of an ECG device.

    Time frame: HRV will be assessed at baseline and 1 week after the last treatment session.

  3. Salivary Cortisol

    Before, immediately after and 30 minutes after the end of the GAT, saliva samples will be collected to measure the concentration of salivary cortisol (SC).

    Time frame: SC will be assessed at baseline and 1 week after the last treatment session.

Other outcomes

  1. State and Trait Anxiety

    State and Trait Anxiety Inventory (STAI) The State-Trait Anxiety Inventory (STAI; 66) is a widely used psychological instrument designed to measure two distinct types of anxiety: state anxiety (temporary, situational anxiety) and trait anxiety (a general tendency to experience anxiety across situations). The STAI consists of 40 self-report items, divided equally into two subscales: the State Anxiety Scale (S-Anxiety) and the Trait Anxiety Scale (T-Anxiety). Each item is rated on a 4-point Likert scale, with scores ranging from 20 to 80 for each subscale, where higher scores indicate greater levels of anxiety.

    Time frame: The STAI will be administered at all study timepoints: baseline, after each treatment session, 1 week and 1 month after the end of treatment.

  2. Empathy

    The Interpersonal Reactivity Index (IRI) (51) is a 28-item questionnaire consisting of 4 discrete seven-item scales i.e. 'Fantasy' (tendency to imaginatively transpose oneself into fictional situations), 'Perspective-Taking' (tendency to spontaneously adopt the psychological viewpoint of others), 'Empathic Concern' (taps the respondents' feelings of warmth, compassion, and concern for others), and 'Personal Distress' (assesses self-oriented feelings of anxiety and discomfort resulting from tense interpersonal settings).

    Time frame: The IRI at baseline and 1 week after the last treatment session.

  3. Well-Being

    The World Health Organisation - Well-Being Index (WHO-5) (52) is a short, self-reported measure designed to evaluate subjective well-being. The WHO-5 is widely used in therapy and research settings to assess general emotional well-being and screen for depression. The index consists of five items, each reflecting a positive aspect of mental health, such as feeling cheerful, calm, active, rested, and interested in daily life. Respondents rate each item on a 6-point Likert scale ranging from 0 (at no time) to 5 (all of the time), based on their experiences over the past two weeks. The total score of the WHO-5 ranges from 0 to 25, with higher scores indicating better well-being. A score below 13 suggests poor well-being. The WHO-5 is valued for its simplicity, brevity, and strong psychometric properties, including high internal consistency and sensitivity to change (52).

    Time frame: The WHO-5 at baseline, 1 week after the last treatment session and one month after the last treatment session.

  4. Resilience

    The Resilience Scale (RS) is a well-validated instrument designed to measure the resilience levels of individuals, reflecting their ability to cope with stress and adversity (53). The RS aims to quantify the personal qualities that enable individuals to thrive despite challenging circumstances. The scale consists of 25 items and respondents rate each item on a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree).

    Time frame: The RS will be administered at baseline, 1 week after the last treatment session and one month after the last treatment session.

  5. Cognitive flexibility

    The Cognitive Flexibility Index (CFI) is a psychometric tool designed to measure an individual's cognitive flexibility, which refers to the mental ability to switch between thinking about different concepts and thinking about multiple concepts simultaneously (54). The CFI assesses cognitive flexibility through 20 self-report items that reflect a person's capacity to adapt to new, unexpected, or changing circumstances, and to shift their thinking and behavior accordingly.

    Time frame: The CFI will be administered at at baseline, 1 week after the last treatment session and one month after the last treatment session.

  6. Person Perception

    The Implicit Association Task - (IAT) is a widely used psychological assessment tool designed to measure implicit attitudes and beliefs that individuals may be unable to report (55). The IAT assesses the strength of automatic associations between mental representations of objects (concepts) and evaluations (attributes). The task involves categorizing words or images that appear on a computer screen into predefined categories as quickly as possible, which reveals underlying implicit biases based on response times.

    Time frame: The IAT will be administered at baseline, 1 week after the last treatment session and one month after the last treatment session.

  7. Mood

    The Positive and Negative Affect Schedule (PANAS) is a widely utilized self-report instrument designed to measure positive and negative affective states (63). Positive affect refers to the extent to which a person feels enthusiastic, active, and alert, whereas negative affect refers to a person's general dimension of distress and unpleasurable engagement. Respondents rate the extent to which they have experienced each particular emotion on a 5-point Likert scale ranging from 1 (very slightly or not at all) to 5 (extremely) over a specified time frame, such as the past week.

    Time frame: The PANAS will be administered at baseline, before and after each treatment session, 1 week and 1 month after the end of treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Data will be made available upon reasonable and motivated request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2025
First posted
Dec 2, 2025
StartActual
Apr 10, 2025
Primary completionEst.
Apr 10, 2027
CompletionEst.
Apr 10, 2028
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07259005
Lead sponsor
Maastricht University
Responsible party
Sponsor
First posted
Dec 2, 2025
Start date
Apr 10, 2025
Primary completion
Apr 10, 2027 (estimated)
Completion
Apr 10, 2028 (estimated)
Last update
Dec 2, 2025

Study contacts

Mauro Cavarra, PhD
Contact
fpn-pim_p154@maastrichtuniversity.nl
‭+31433882210‬
Kim PC Kuypers, PhD
principal investigator · Maastricht University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion